TY - JOUR
T1 - Prevalence of hypertensive diseases and treated hypertensive patients in Japan
T2 - A nationwide administrative claims database study
AU - Waki, Takashi
AU - Miura, Katsuyuki
AU - Tanaka-Mizuno, Sachiko
AU - Ohya, Yusuke
AU - Node, Koichi
AU - Itoh, Hiroshi
AU - Rakugi, Hiromi
AU - Sato, Jumpei
AU - Goda, Kazuo
AU - Kitsuregawa, Masaru
AU - Ishikawa, Tomoki
AU - Mitsutake, Naohiro
N1 - Funding Information:
TW, KM, SMT, YO, JS, KG, MK, TI and NM declare that they have no conflicts of interest to disclose. KN has received honoraria and fees for promotional materials from Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kowa Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; research funding from Asahi Kasei Corporation, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Teijin Pharma Ltd.; and a scholarship or donation from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Medtronic Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. HI has an employment/leadership position/advisory role at SBI Pharmaceuticals Co., Ltd., NIPRO Corporation and Wakunaga Pharmaceutical Co., Ltd.; has received honoraria and fees for promotional materials from Mitsubishi Tanabe Pharma Corporation, MSD K.K., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Kao Corporation and Ono Pharmaceutical Co., Ltd. has received research funding from Shionogi & Co., Ltd. and Oriental Yeast Co., Ltd.; and a scholarship or donation from Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation., Abbott Japan Co., Ltd., Bayer Yakuhin, Ltd., Kyowa Kirin Co., Ltd. and LifeScan Japan K.K. HR has received honoraria and fees for promotional materials from Daiichi-Sankyo Co., Ltd., MSD K.K., and Takeda Pharmaceutical Co., Ltd., and a scholarship or donation from Daiichi-Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Novartis Pharma K.K.
Funding Information:
We thank DMC Corp. for providing editorial and medical writing support, which was funded by the Department of Public Health, Shiga University of Medical Science.
Funding Information:
This research is supported by a Grant-in-Aid for Scientific Research (Grant Number: H30-Seisaku-Shitei-007) from the Ministry of Health, Labour and Welfare, Japan.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to The Japanese Society of Hypertension.
PY - 2022/7
Y1 - 2022/7
N2 - We investigated the prevalence of hypertensive patients and treated hypertensive patients using a Japanese nationwide administrative claims database. We analyzed national database data from 2014, including all claims data, provided by the Ministry of Health, Labour and Welfare of Japan. Hypertensive diseases were identified using Japanese standardized disease codes. Among hypertensive patients, treated hypertensive patients were defined by the prescription of any antihypertensive medication, identified using national health insurance price listing codes. We calculated and compared the number and age-adjusted prevalence of hypertensive patients and treated hypertensive patients by prefecture and the proportion of these patients by the size of medical facilities. In 2014, approximately 27 million Japanese people were identified as hypertensive, among which 89.6% were treated. The age-adjusted prevalence of hypertensive patients (per 100,000 persons) among women and men was 21,414 and 21,084, respectively. The age-adjusted prevalence of treated hypertensive patients (per 100,000 persons) among women and men was 19,118 and 18,974, respectively. While the prevalence of hypertensive and treated hypertensive patients varied geographically, the prevalence remained similar between the sexes. Approximately 59% of hypertensive patients visited clinics (0 to 19 beds) in Japan. In Japan, 27 million people were diagnosed with hypertensive diseases, and approximately 90% of these patients were treated with any antihypertensive medication in 2014. The distribution of hypertensive patients varied geographically throughout Japan.
AB - We investigated the prevalence of hypertensive patients and treated hypertensive patients using a Japanese nationwide administrative claims database. We analyzed national database data from 2014, including all claims data, provided by the Ministry of Health, Labour and Welfare of Japan. Hypertensive diseases were identified using Japanese standardized disease codes. Among hypertensive patients, treated hypertensive patients were defined by the prescription of any antihypertensive medication, identified using national health insurance price listing codes. We calculated and compared the number and age-adjusted prevalence of hypertensive patients and treated hypertensive patients by prefecture and the proportion of these patients by the size of medical facilities. In 2014, approximately 27 million Japanese people were identified as hypertensive, among which 89.6% were treated. The age-adjusted prevalence of hypertensive patients (per 100,000 persons) among women and men was 21,414 and 21,084, respectively. The age-adjusted prevalence of treated hypertensive patients (per 100,000 persons) among women and men was 19,118 and 18,974, respectively. While the prevalence of hypertensive and treated hypertensive patients varied geographically, the prevalence remained similar between the sexes. Approximately 59% of hypertensive patients visited clinics (0 to 19 beds) in Japan. In Japan, 27 million people were diagnosed with hypertensive diseases, and approximately 90% of these patients were treated with any antihypertensive medication in 2014. The distribution of hypertensive patients varied geographically throughout Japan.
KW - Administrative claims data
KW - Exhaustive study
KW - Geographical distribution
KW - Hypertensive disease
KW - National database
UR - http://www.scopus.com/inward/record.url?scp=85131527451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131527451&partnerID=8YFLogxK
U2 - 10.1038/s41440-022-00924-1
DO - 10.1038/s41440-022-00924-1
M3 - Article
C2 - 35681039
AN - SCOPUS:85131527451
SN - 0916-9636
VL - 45
SP - 1123
EP - 1133
JO - Hypertension Research
JF - Hypertension Research
IS - 7
ER -